The EU General Court upheld the EC’s 2005 decision to fine AstraZeneca for abusing the patent system to delay they market entry of generic competitors for its ulcer drug Losec. The court reduced the fine from 60 euro to 53 euro, finding that the evidence was insufficient to prove wrong-doing in Denmark and Norway.